DE1158966B - Process for the preparation of 6-chloro-1,2ª‡-methylene-í¸-17ª‡-hydroxyprogesterone esters - Google Patents

Process for the preparation of 6-chloro-1,2ª‡-methylene-í¸-17ª‡-hydroxyprogesterone esters

Info

Publication number
DE1158966B
DE1158966B DESCH29643A DESC029643A DE1158966B DE 1158966 B DE1158966 B DE 1158966B DE SCH29643 A DESCH29643 A DE SCH29643A DE SC029643 A DESC029643 A DE SC029643A DE 1158966 B DE1158966 B DE 1158966B
Authority
DE
Germany
Prior art keywords
methylene
chloro
preparation
hydroxyprogesterone
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DESCH29643A
Other languages
German (de)
Inventor
Dr Rudolf Wiechert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DESCH29643A priority Critical patent/DE1158966B/en
Priority to CH214862A priority patent/CH417576A/en
Priority to GB14061/62A priority patent/GB973908A/en
Priority to US189724A priority patent/US3234093A/en
Priority to BR138435/62A priority patent/BR6238435D0/en
Priority to BE616989A priority patent/BE616989A/en
Publication of DE1158966B publication Critical patent/DE1158966B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Description

BUNDESREPUBLIK DEUTSCHLAND KL. 12 O 25/05FEDERAL REPUBLIC OF GERMANY KL. 12 O 25/05 INTERNAT. KL. C 07 CINTERNAT. KL. C 07 C

DEUTSCHESGERMAN

PATENTAMTPATENT OFFICE

AUSLEGESCHRIFT 1158 966 EXPLAINING EDITORIAL 1158 966

Sch 29643 IVb/12 οSch 29643 IVb / 12 ο

ANMELDETAG: 29. APRIL 1961REGISTRATION DATE: APRIL 29, 1961

BEKANNTMACHUN G DER ANMELDUNG UNDAUSGABEDER AUSLEGESCHRIFT: 12. DEZEMBER 1963NOTIFICATION OF REGISTRATION AND ISSUE OF EDITORIAL: DECEMBER 12, 1963

Die Erfindung betrifft die Einführung eines 6-ständigen Chloratoms in 1.2a-Methylen-zJ6-17a-hydroxyprogesteronester. Das erfindungsgemäße Verfahren besteht darin, daß man l,2a-Methylenzle-17a-hydroxyprogesteronester in an sich bekannter Weise, vorzugsweise mittels einer Percarbonsäure. insbesondere Benzoepersäure, zunächst in die entsprechenden 6,7a-Epoxyde überführt, daß man diese dann mit Chlorwasserstoffsäure, vorzugsweise in Eisessiglösung, behandelt, wobei in einer Operation der Cyclopropanring unter Bildung einer la-Chlormethylgruppe und der Epoxydring unter Wasserabspaltung und Ausbildung der 6-Chlor-zl ^Gruppierung geöffnet werden, und daß man schließlich die la-Chlormethylgruppe des Reaktionsproduktes mit einer vorzugsweise organischen Base, insbesondere Collidin, in die 1,2a-Methylengruppe zurückverwandelt, wie folgende Formelübersicht näher erläutert :The invention relates to the introduction of a 6-chlorine atom in 1,2a-methylene-zJ 6 -17a-hydroxyprogesterone ester. The inventive method is that one l, 2a-e Methylenzl -17a-hydroxyprogesteronester in a known manner, preferably by means of a percarboxylic acid. in particular benzoic acid, first converted into the corresponding 6,7a-epoxides, that this is then treated with hydrochloric acid, preferably in glacial acetic acid solution, whereby in one operation the cyclopropane ring with formation of a la-chloromethyl group and the epoxy ring with elimination of water and formation of 6-chlorine -zl ^ grouping are opened, and that finally the la-chloromethyl group of the reaction product is converted back into the 1,2a-methylene group with a preferably organic base, in particular collidine, as explained in more detail below:

Verfahren zur HerstellungMethod of manufacture

von o-Chlor-l^a-methylen-of o-chlorine-l ^ a-methylene

Δ6-17a-hydroxyprogesteronestern Δ 6 - hydroxyprogesteronestern 17a

Anmelder:Applicant:

Schering Aktiengesellschaft, Berlin N 65, Müllerstr. 170-172Schering Aktiengesellschaft, Berlin N 65, Müllerstr. 170-172

Dr. Rudolf Wiechert, Berlin-Lichterfelde West, ist als Erfinder genannt wordenDr. Rudolf Wiechert, Berlin-Lichterfelde West, has been named as the inventor

CH3 CH 3

OacOac

CH2ClCH 2 Cl

CH3 CH 3

OacOac

CHrCHr

ac = Acylac = acyl

Die Verfahrensprodukte. insbesondere das gerade ausreichenden Mindestmengen zeigt deut-The process products. in particular the just sufficient minimum quantity shows clearly

17-Acetat, sind überraschend stark wirksame Gesta- lieh die überlegene Wirksamkeit des 6-Chlor-17-acetate, are surprisingly strong stems borrowed the superior effectiveness of 6-chloro

gene, vor allem bei peroraler Applikation. Die 50 I,2a-methylen-zi6-17a-hydroxyprogesteron-acetatsgenes, especially for peroral application. The 50 I, 2a-methylene-zi 6 -17a-hydroxyprogesterone acetate

folgende Gegenüberstellung der zur Erzielung eines gegenüber den als stark wirksam bekannten Gesta-The following comparison of the gestures that are known to be highly effective in order to achieve

positiven Clauberg-Tests an infantilen Kaninchen genen:positive Clauberg tests on infantile rabbits genes:

309 768/430309 768/430

Verbindunglink

6-Chlor-1.2a-methylenzl6-17a-hydroxyprogesteron-acetat ....6-chloro-1.2a-methylenzl 6 -17a-hydroxyprogesterone acetate ....

19-Nor-17a-hydroxyprogesteron-acetat ....19-nor-17a-hydroxyprogesterone acetate ....

17a-Hydroxy-progesteronacetat 17a-hydroxy-progesterone acetate

19-Nor-17a-äthinyltestosteron 19-nor-17a-ethinyltestosterone

l^Nor-na-äthinyltestosteron-acetat l ^ Nor-na-ethinyl testosterone acetate

Erforderliche DosisRequired dose

in Milligramm beiin milligrams

subcutaner I peroralersubcutaneous I peroral

ApplicationApplication

0.0030.003

0,0030.003

0.030.03

0,060.06

0,030.03

0,010.01

0.10.1

0,90.9

0,10.1

0.030.03

Die Ester des 6-Chlor-I,2a-methylen-zl6-17a-hydroxylprogesterons zeigen ähnliche Wirkungssteigerungen gegenüber den entsprechenden Vergleichssubstanzen. Bei den höheren Homologen, angefangen etwa vom Önanthat, zeigt sich außerdem eine wertvolle Protraktion der Wirksamkeit. An Stelle von Estern der aliphatischen Carbonsäuren können auch die bei der therapeutischen Verwendung von Steroiden gebräuchlichen Ester anderer Carbonsäuren, z. B. der alicyclischen. aromatischen oder gemischt offenkettig-cyclischen Carbonsäuren in analoger Weise hergestellt werden. Sie zeigen gleichartige ähnlich hohe Wirksamkeiten.The esters of 6-chloro-1,2a-methylene-zl 6 -17a-hydroxylprogesterone show similar increases in activity compared to the corresponding comparison substances. In the case of the higher homologues, beginning for example with enanthate, there is also a valuable reduction in effectiveness. Instead of esters of aliphatic carboxylic acids, the esters of other carboxylic acids commonly used in the therapeutic use of steroids, e.g. B. the alicyclic. aromatic or mixed open-chain cyclic carboxylic acids are prepared in an analogous manner. They show similar, similarly high efficacies.

Beispiel 1example 1

2.34 g 1,2a - Methylen - /J4·6 - pregnadien - 17a - ol-3.20-dion-17-acetat werden in 18,25 ml Äthylenchlorid, das 844 mg Benzoepersäure enthält, gelöst. Die Lösung wird 16 Stunden bei +50C und 7 Stunden bei Zimmertemperatur aufbewahrt. Es wird dann mit Methylenchlorid verdünnt und mit wäßriger Eisen(II)-sulfat-Lösung, Natriumhydrogencarbonatlösung und mit Wasser neutral gewaschen. Die organische Phase wird nach Trocknung über Natriumsulfat zur Trockne eingeengt. 1,62 g des so erhaltenen rohen l,2a-Methylen-6,7a-oxido-J4-pregnen-17a-ol-3,20-dion-17-acetats werden in 109 ml Eisessig gelöst. Diese Lösung wird dann bei Raumtemperatur mit Salzsäuregas gesättigt und 20 Stunden aufbewahrt. Es wird dann mit Methylenchlorid verdünnt und mit Wasser neutral gewaschen. Die organische Phase wird nach Trocknung über Natriumsulfat zur Trockne eingeengt. Das so erhaltene rohe 6-Chlor-1 a-chlormethyl-J4 6-pregnadien-17a-ol-3,20-dion-17-acetat wird in 20 ml Collidin 20 Minuten unter Stickstoff zum Sieden erhitzt. Nach dem Verdünnen mit Äther wird mit 4 n-Chlorwasserstoffsäure und mit Wasser neutral gewaschen.2.34 g of 1,2a - methylene - / I 4 · 6 - pregnadiene - 17a - ol-3.20-dione-17-acetate are dissolved in 18.25 ml of ethylene chloride containing 844 mg of benzoeperic acid. The solution is kept for 16 hours at +5 0 C and 7 hours at room temperature. It is then diluted with methylene chloride and washed neutral with aqueous iron (II) sulfate solution, sodium hydrogen carbonate solution and with water. After drying over sodium sulfate, the organic phase is concentrated to dryness. 1.62 g of the crude 1,2a-methylene-6,7a-oxido-J 4 -pregnen-17a-ol-3,20-dione-17-acetate thus obtained are dissolved in 109 ml of glacial acetic acid. This solution is then saturated with hydrochloric acid gas at room temperature and stored for 20 hours. It is then diluted with methylene chloride and washed neutral with water. After drying over sodium sulfate, the organic phase is concentrated to dryness. The crude 6-chloro- 1α-chloromethyl-J 4 6 -pregnadien-17a-ol-3,20-dione-17-acetate obtained in this way is heated to boiling in 20 ml of collidine for 20 minutes under nitrogen. After dilution with ether, it is washed neutral with 4N hydrochloric acid and with water.

Der nach dem Trocknen über Natriumsulfat und Einengen zur Trockne verbleibende Rückstand wird über Silicagel Chromatographien. Mit einem Benzol-Essigester-Gemisch 19:1 eluiert man 900 mg 6 - Chlor -1,2a - methylen - Δ4·6 - pregnadien -17a - ol-3,20-dion-17-acetat, das, umkristallisiert aus Isopropyläther, bei F. = 200 bis 2010C schmilzt. UV = £28i = 17 820 (Methanol).The residue remaining after drying over sodium sulfate and concentration to dryness is chromatographed on silica gel. With a benzene-ethyl acetate mixture 19: 1, 900 mg of 6-chloro-1,2a-methylene- Δ 4 · 6 - pregnadiene-17a-ol-3,20-dione-17-acetate are eluted, which is recrystallized from isopropyl ether , melts at F. = 200 to 201 0 C. UV = £ 2 8i = 17,820 (methanol).

Beispiel 2Example 2

8,7 g 1,2a - Methylen - zt4·6 - pregnadien - 17a - ol-3,20-dion-17-capronat werden mit 2,77 g Benzoepersäure in 52,9 ml Äthylenchlorid 17 Stunden bei 5° C und 7 Stunden bei Raumtemperatur aufbewahrt. Es wird dann, wie im Beispiel 1 beschrieben, aufgearbeitet und das so erhaltene rohe l,2a-Methylen - 6,7a - oxido - Δ4 - pregnen -17a - öl - 3,20 - dion-17-capronat in 585 ml Eisessig gelöst. Diese Lösung wird bei Raumtemperatur mit Salzsäuregas gesättigt und 20 Stunden aufbewahrt, dann mit Methylenchlorid verdünnt und mit Wasser neutral gewaschen.8.7 g of 1,2a-methylene-zt 4 · 6 -pregnadiene-17a-ol-3,20-dione-17-capronate are mixed with 2.77 g of benzoic acid in 52.9 ml of ethylene chloride for 17 hours at 5 ° C and Stored for 7 hours at room temperature. It is then, as described in Example 1, worked up and the crude 1,2a-methylene-6,7a-oxido- Δ 4 - pregnen-17a-oil-3.20-dione-17-capronate in 585 ml of glacial acetic acid solved. This solution is saturated with hydrochloric acid gas at room temperature and stored for 20 hours, then diluted with methylene chloride and washed neutral with water.

Die organische Phase wird nach Trocknung überThe organic phase is dried over

Natriumsulfat zur Trockne eingeengt. Man erhält so 9,4 g rohes 6-Chlor-la-chlormethyl-zl4'6-pregnadien-17a-ol-3,20-dion-17-capronat, die, gelöst in 87 ml frisch destilliertem Collidin, 30 Minuten unter Stickstoff am Rückfluß erhitzt werden. Es wird aufgearbeitet und chromatographiert, wie im Beispiel 1 beschrieben.
Man erhält 3,1 g 6-Chlor-l,2a-methylen-zl4'6-pre-
Sodium sulfate concentrated to dryness. This gives 9.4 g of crude 6-chloro-la-chloromethyl-zl 4 ' 6 -pregnadien-17a-ol-3,20-dione-17-capronate, which, dissolved in 87 ml of freshly distilled collidine, takes 30 minutes Refluxed with nitrogen. It is worked up and chromatographed as described in Example 1.
3.1 g of 6-chloro-1,2a-methylene-zl 4 ' 6 -pre- are obtained

gnadien-17a-ol-3,20-dion-17-capronat als öl.gnadien-17a-ol-3,20-dione-17-capronate as an oil.

UV = £282 = Π 500.UV = £ 2 82 = Π 500.

Analyse:Analysis:

Berechnet
gefunden
Calculated
found

... Cl 7,5%;
... Cl 7,4%.
... Cl 7.5%;
... Cl 7.4%.

Claims (1)

PATENTANSPRUCH:PATENT CLAIM: Verfahren zur Herstellung von 6-Chlor-l,2a-methylen-de-17a-hydroxyprogesteronestern, dadurch gekennzeichnet, daß man einen l,2a-Methylende-17a-hydroxyprogesteronester in an sich bekannter Weise, vorzugsweise mit einer Percarbonsäure, insbesondere Benzoepersäure, epoxydiert, das entsprechende 6,7a-Epoxyd mit Chlorwasserstoffsäure, vorzugsweise in Eisessiglösung, behandelt, und die erhaltene la-Chlormethyl-6-chlor-zle-Verbindung mit einer vorzugsweise organischen Base, insbesondere Collidin, umsetzt.Process for the preparation of 6-chloro- 1,2a-methylene-d e -17a-hydroxyprogesterone esters, characterized in that a 1,2a-methylend e -17a-hydroxyprogesterone ester is used in a manner known per se, preferably with a percarboxylic acid, in particular benzoeperic acid , epoxidized, treated the corresponding 6,7a-epoxide with hydrochloric acid, preferably in glacial acetic acid solution, and the resulting la-chloromethyl-6-chloro-zl e compound is reacted with a preferably organic base, in particular collidine.
DESCH29643A 1961-04-29 1961-04-29 Process for the preparation of 6-chloro-1,2ª‡-methylene-í¸-17ª‡-hydroxyprogesterone esters Pending DE1158966B (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DESCH29643A DE1158966B (en) 1961-04-29 1961-04-29 Process for the preparation of 6-chloro-1,2ª‡-methylene-í¸-17ª‡-hydroxyprogesterone esters
CH214862A CH417576A (en) 1961-04-29 1962-02-22 Process for the preparation of 1,2a-methylene-6-17a-hydroxy-progesterone esters halogenated in the 6-position
GB14061/62A GB973908A (en) 1961-04-29 1962-04-11 1ª‡.2ª‡-methylene-í¸-17ª‡-hydroxy-progesterone-17-carboxylic esters halogenated in 6-position and a process for their manufacture
US189724A US3234093A (en) 1961-04-29 1962-04-24 6-chloro-1, 2alpha-methylene-delta6-17alpha-hydroxyprogesterone compounds and compositions
BR138435/62A BR6238435D0 (en) 1961-04-29 1962-04-25 PROCESS FOR THE PREPARATION OF NEW 1,2 ALPHA-METHYLENE-DELTA-617 ALPHA-HYDROXY-PROGESTERONE HALOGENATED IN POSITION 6
BE616989A BE616989A (en) 1961-04-29 1962-04-27 Process for the preparation of 1,2alpha-methylene-Delta <6> -17alpha-hydroxyprogesterone esters halogenated in position 6 and products obtained

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DESCH29643A DE1158966B (en) 1961-04-29 1961-04-29 Process for the preparation of 6-chloro-1,2ª‡-methylene-í¸-17ª‡-hydroxyprogesterone esters

Publications (1)

Publication Number Publication Date
DE1158966B true DE1158966B (en) 1963-12-12

Family

ID=7431494

Family Applications (1)

Application Number Title Priority Date Filing Date
DESCH29643A Pending DE1158966B (en) 1961-04-29 1961-04-29 Process for the preparation of 6-chloro-1,2ª‡-methylene-í¸-17ª‡-hydroxyprogesterone esters

Country Status (6)

Country Link
US (1) US3234093A (en)
BE (1) BE616989A (en)
BR (1) BR6238435D0 (en)
CH (1) CH417576A (en)
DE (1) DE1158966B (en)
GB (1) GB973908A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359154A1 (en) * 2002-04-29 2003-11-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Further syntheses of cyproterone acetate

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050218A (en) * 1964-10-13
US3401163A (en) * 1965-10-21 1968-09-10 Squibb & Sons Inc Preparation of methylene steroids
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
DE2345377A1 (en) * 1973-09-06 1975-03-20 Schering Ag PHARMACEUTICAL PREPARATION I
GB1570524A (en) * 1976-03-11 1980-07-02 Unilever Ltd Cosmetic
DE2712861C2 (en) * 1977-03-21 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 17-acetoxy-6-chloro-15β-hydroxy-1α, 2α-methylene-4,6-pregnadiene-3,20-dione, process for its preparation and medicament containing it
DE3331824A1 (en) * 1983-09-01 1985-03-21 Schering AG, Berlin und Bergkamen, 1000 Berlin METHOD FOR PRODUCING 17 (ALPHA) -ACYLOXY-6-CHLORINE-1 (ALPHA), 2 (ALPHA) -METHYLENE-3,20-DIONES
US5439901A (en) * 1993-07-23 1995-08-08 The Procter & Gamble Company Cyproterone thiopivalate
US5468104A (en) 1994-08-10 1995-11-21 Fatigue Technology, Inc. Wall nut assembly
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6613758B1 (en) 1999-04-02 2003-09-02 Barr Laboratories, Inc. Method for treating osteoporosis in castrated prostatic cancer patients
US20040024230A1 (en) * 2002-04-29 2004-02-05 Boehringer Ingelheim International Gmbh Synthesis of cyproterone acetate
RU2422450C2 (en) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. New phosphorus-containing thymomimetic drugs
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
ATE547394T1 (en) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPANE-1- AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLERosis AND CARDIOVASCULAR DISEASES
WO2009126825A1 (en) 2008-04-09 2009-10-15 Pherin Pharmaceuticals, Inc. Steroid treatment for hot flashes
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
MA38114A1 (en) 2012-12-03 2017-12-29 Pfizer New selective androgenic modulators

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359154A1 (en) * 2002-04-29 2003-11-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Further syntheses of cyproterone acetate
WO2003092578A2 (en) * 2002-04-29 2003-11-13 Boehringer Ingelheim International Gmbh Further syntheses of cyproterone acetate
WO2003092578A3 (en) * 2002-04-29 2004-04-08 Boehringer Ingelheim Int Further syntheses of cyproterone acetate

Also Published As

Publication number Publication date
CH417576A (en) 1966-07-31
US3234093A (en) 1966-02-08
GB973908A (en) 1964-11-04
BR6238435D0 (en) 1973-05-24
BE616989A (en) 1962-10-29

Similar Documents

Publication Publication Date Title
DE1158966B (en) Process for the preparation of 6-chloro-1,2ª‡-methylene-í¸-17ª‡-hydroxyprogesterone esters
DE2109555C3 (en) New 15 a, 16 a -methylene steroids, drugs containing them and processes for their production
DE1263000B (en) New process for the production of mixtures of delta 1,3,5 (10) -3-oxysteroids and delta 1,3,5 (10) 9 (11) -3-oxysteroids or of delta 1,3,5 (10) -3 oxysteroids
DE1643017C3 (en) Process for the preparation of e-chloro-1,2alpha-methylene-delta nor 4,6-pregnadienes
DE2037403C3 (en) 3-OXO-7 a, 17 a -dimethyl- 13 ß -ethyl-17 ß -hydroxy-gona-4,9,11-triene, process for its production, intermediate products and drugs
AT257060B (en) Process for the preparation of new 3-enol ethers of the 6-methyl-3-oxo-Δ &lt;4&gt; -steroids of the androstane, 19-norandrostane, pregnane and 19-norpregnane series
DE1493156C (en) Progestin-active 6 halo 1 alpha, 2-alpha methylene delta 4,6 pregnadiene compounds and process for their preparation
DE1264441B (en) Process for the production of 17alpha-AEthynyl-delta 5 (10-19-nor-androsten-17beta-ol-3-one and 17alpha-AEthynil-19-nor-testosterone and its esters
AT275054B (en) Process for the production of new 9β, 10α-steroids
DE957661C (en) Process for the preparation of 17-oxy-20-keto-21acyl-oxypregnanes
DE1186854B (en) Process for the preparation of 6-fluoro-1,2alpha-methylene-delta-17alpha-hydroxyprogestn
DE1215702B (en) Process for the preparation of 1alpha-alkylthio-3-keto-androstanes
DE1187238B (en) Method of making steroids
AT253141B (en) Process for the manufacture of new steroids
AT242304B (en) Process for the preparation of new enol ethers from 3-keto-5α-androstane derivatives
AT220298B (en) Process for the production of new 6β-methyl-3-oxo-Δ &lt;4&gt; -steroids
DE725280C (en) Process for the preparation of compounds of the cyclopentanopolyhydrophenanthrene series
AT238382B (en) Process for the preparation of 17α-acyloxy-6α-methyl-16-methylenepregn-4-en-3,20-dione
DE2031205C3 (en) Process for the preparation of 17-monoesters of 17 alpha, 21-dihydroxy-20-keto steroids and prednisolone 17 benzoate
DE1170944B (en) Process for the preparation of 6ª ‰, 19-oxydosteroids
DE1643017B2 (en) PROCESS FOR THE PRODUCTION OF 6-CHLORO-1,2ALPHA-METHYLENE DELTA HIGH 4,6-PREGNADIENES
DE1252679B (en) Process for the preparation of zlM.5 (10) -A-homo-oestratrien-3-one derivatives
CH473795A (en) Process for making new 9B, 10a steroids
DE1243682B (en) Process for the preparation of therapeutically active steroid compounds
DE1223374B (en) Process for the preparation of 1alpha-acylthio-3-keto-androstanes